ProPhase Labs, Inc. Deferred Federal Income Tax Expense (Benefit)
ProPhase Labs, Inc. (PRPH) reported Deferred Federal Income Tax Expense (Benefit) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-06-01.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2026-06-01
- ProPhase Labs, Inc. deferred federal income tax expense (benefit) for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- ProPhase Labs, Inc. deferred federal income tax expense (benefit) for fiscal 2024 was $5.34M.
- ProPhase Labs, Inc. deferred federal income tax expense (benefit) for fiscal 2023 was -$5.46M, a 7681.94% decline from fiscal 2022.
- ProPhase Labs, Inc. deferred federal income tax expense (benefit) for fiscal 2022 was $72.00K.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month | Deferred Federal Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-06-01 | |
| 2024-12-31 | $5.34M 10-K · filed 2026-06-01 | |
| 2023-12-31 | -$5.46M 10-K · filed 2025-04-01 | |
| 2022-12-31 | $72.00K 10-K · filed 2024-03-29 | |
| 2021-12-31 | -$1.51M 10-K · filed 2023-03-29 | |
| 2018-12-31 | -$86.00K 10-K · filed 2019-03-26 | |
| 2017-12-31 | $15.41M 10-K · filed 2019-03-26 | $15.78M 10-K · filed 2018-03-28 |
| 2016-12-31 | -$936.00K 10-K/A · filed 2018-08-20 | |
| 2015-12-31 | -$1.40M 10-K/A · filed 2018-08-20 | |
| 2014-12-31 | -$2.47M 10-K · filed 2017-02-24 | |
| 2013-12-31 | $1.22M 10-K · filed 2016-03-29 | |
| 2012-12-31 | -$618.00K 10-K · filed 2015-03-27 | |
| 2011-12-31 | -$877.00K 10-K · filed 2014-03-27 | |
| 2010-12-31 | -$107.00K 10-K · filed 2013-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |